Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2019-10-07 Regulatory Filings
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to the SEC regarding the withdrawal of a request for acceleration of effectiveness of a Registration Statement on Form S-1. It does not contain financial data, report content, or detailed disclosures. It is a regulatory communication related to a filing process rather than a report or announcement of financial results. Given its brevity (828 characters) and nature as a formal correspondence withdrawing a filing request, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2019-10-07 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 95% confidence The document is a correspondence letter addressed to the SEC regarding a Registration Statement on Form S-1 for Titan Pharmaceuticals, Inc. It is a request for acceleration of the effectiveness of the registration statement, signed by an underwriter representative. The content is related to a capital raising process but does not contain financial data or results itself. It is a regulatory communication about a financing filing, not the filing or report itself. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not an announcement of a report publication, so it is not RPA. Confidence is high due to clear context and content.
2019-10-04 English
Regulatory Filings 2019
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the Securities and Exchange Commission requesting acceleration of the effective date of a Registration Statement on Form S-1. It is a correspondence related to a regulatory filing process, specifically about the registration statement effectiveness, not the registration statement itself or any financial report. The document is short (1463 characters) and serves as a formal request rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence that do not fit other categories.
2019-10-04 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Securities and Exchange Commission regarding the withdrawal of a request for acceleration of a Registration Statement on Form S-1. It is a regulatory communication related to the registration process of securities, not a financial report or announcement of financial results. The document is short (853 characters) and does not contain financial data or detailed report content. It is a regulatory filing related to securities registration procedures, fitting best under the Regulatory Filings (RNS) category as a general regulatory announcement.
2019-10-03 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a correspondence letter addressed to the SEC regarding a Registration Statement on Form S-1 for Titan Pharmaceuticals, Inc. It is a request for acceleration of the effectiveness of the registration statement, signed by an underwriter representative. The content is related to a capital raising process but is not a financial report or earnings release. It is a regulatory filing related to the registration process and compliance with securities laws, not a report or announcement of financial results. The document length is short and it is a formal communication with the SEC, fitting the Regulatory Filings (RNS) category as a general regulatory announcement.
2019-10-02 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Securities and Exchange Commission requesting acceleration of the effective date for a Registration Statement on Form S-1. It is a correspondence related to a regulatory filing process, specifically about the registration statement effectiveness, not the registration statement itself or any financial report. The document is short (1465 characters) and is a formal request letter, not a report or financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2019-10-01 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.